BARDA boosts Pfenex anthrax vaccine award
This article was originally published in Scrip
Executive Summary
The US Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services, has modified its contract with Pfenex, which supports the development of a next-generation recombinant protective antigen (rPA)-anthrax vaccine, and simultaneously exercised an option associated with the San Diego-based biotech's July 2010 award – boosting it by $8m, bringing the potential worth to $23.9m.